DAPK-based drug resistance against erlotin and cetuximab in cell lines of non-small cell lung cancer or head and neck squamous cell carcinoma was found to be caused by hypermethylation of the DAPK-encoding gene [180]; this could be reproduced by siRNA-mediated knockdown of DAPK while a gene transfers rescued resistance. This evidence concerns the gene DAPK1 and head and neck squamous cell carcinoma.